L3VLUP
ProSign in

A · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • A
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterAVRTX
Q3 202018 holders, $7.1bn31 holders, $21.9bn
Q4 202017 holders, $7.8bn30 holders, $18.4bn
Q1 202120 holders, $7.2bn31 holders, $15.4bn
Q2 202119 holders, $8.5bn30 holders, $12.7bn
Q3 202122 holders, $8.5bn35 holders, $10.1bn
Q4 202122 holders, $8.5bn28 holders, $12.4bn
Q1 202224 holders, $6.8bn23 holders, $16.1bn
Q2 202224 holders, $6.5bn25 holders, $18.1bn
Q3 202219 holders, $4.5bn22 holders, $18.4bn
Q4 202224 holders, $6.2bn28 holders, $18.4bn
Q1 202327 holders, $6.0bn26 holders, $21.4bn
Q2 202321 holders, $4.7bn27 holders, $24.7bn
Q3 202321 holders, $4.0bn33 holders, $24.3bn
Q4 202316 holders, $4.9bn32 holders, $28.6bn
Q1 202412 holders, $5.3bn31 holders, $29.8bn
Q2 202413 holders, $4.2bn29 holders, $33.4bn
Q3 202416 holders, $4.9bn27 holders, $33.5bn
Q4 202417 holders, $4.3bn26 holders, $28.5bn
Q1 202517 holders, $3.8bn21 holders, $35.4bn
Q2 202513 holders, $3.8bn21 holders, $32.3bn
Q3 202515 holders, $3.9bn22 holders, $25.9bn
Q4 202517 holders, $4.6bn26 holders, $31.8bn
Q1 202621 holders, $4.0bn25 holders, $31.8bn
Q2 202615 holders, $5.1bn26 holders, $34.6bn
A

Agilent Technologies Inc

Holders
13
Reported value
$4.2bn
Buyers
10
Sellers
4

Breadth +6 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
29
Reported value
$33.4bn
Buyers
12
Sellers
18

Breadth -6 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only A (6)

Balyasny Asset Management LLC, Harris Associates LP, Millennium Management LLC, Point72 Asset Management LP, Soros Fund Management LLC, Tudor Investment Corp

Only VRTX (22)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →